Interfering cancer with polymeric siRNA nanomedicines

Journal of Biomedical Nanotechnology

Volumn 10, Issue 1, 2014, Pages 50-66

  Tiram, Galia ^a   Scomparin, Anna ^a   Ofek, Paula ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer Therapeutics; miRNA; Oligonucleotides; Polymer Therapeutics; Polymeric Nanoparticles; Polyplexes; RNA Interference; siRNA

Indexed keywords

CANCER THERAPEUTICS; MIRNA; POLYMER THERAPEUTICS; POLYMERIC NANOPARTICLES; POLYPLEXES; RNA INTERFERENCE; SIRNA;

CELL MEMBRANES; DISEASES; GENE THERAPY; LIPOSOMES; NANOPARTICLES; OLIGONUCLEOTIDES; RNA; TISSUE;

FUNCTIONAL POLYMERS;

CHITOSAN; CYCLODEXTRIN; DENDRIMER; DEXTRAN; LIPOFECTAMINE; MACROGOL; MICRORNA; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; OLIGONUCLEOTIDE; POLY(AMINOACIDIC) POLYMER; POLYELECTROLYTE; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CANCER GENE THERAPY; CELL MEMBRANE; CHANNEL GATING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SELECTIVITY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; IN VIVO GENE TRANSFER; MEMBRANE PERMEABILITY; NANOMEDICINE; NEOPLASM; NONHUMAN; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; REVIEW; RNA INTERFERENCE; RNA STABILITY; TARGET CELL; TARGET ORGAN;

ANIMALS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; NANOCONJUGATES; NANOMEDICINE; NEOPLASMS; POLYMERS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84889014794     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1715     Document Type: Review

References (138)

1. D. Castanotto and J. J. Rossi, The promises and pitfalls of RNAinterference- based therapeutics. Nature 457, 426 (2009).
2. E. S. Lander, L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, K. Devon, K. Dewar, M. Doyle, W. FitzHugh, R. Funke, D. Gage, K. Harris, A. Heaford, J. Howland, L. Kann, J. Lehoczky, R. LeVine, P. McEwan, K. McKernan, J. Meldrim, J. P. Mesirov, C. Miranda, W. Morris, J. Naylor, C. Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, N. Stange- Thomann, N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough, S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P. Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S. Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray, L. Matthews, S. Mercer, S. Milne, J. C. Mullikin, A. Mungall, R. Plumb, M. Ross, R. Shownkeen, S. Sims, R. H. Waterston, R. K. Wilson, L. W. Hillier, J. D. McPherson, M. A. Marra, E. R. Mardis, L. A. Fulton, A. T. Chinwalla, K. H. Pepin, W. R. Gish, S. L. Chissoe, M. C. Wendl, K. D. Delehaunty, T. L. Miner, A. Delehaunty, J. B. Kramer, L. L. Cook, R. S. Fulton, D. L. Johnson, P. J. Minx, S. W. Clifton, T. Hawkins, E. Branscomb, P. Predki, P. Richardson, S. Wenning, T. Slezak, N. Doggett, J. F. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M. Frazier, R. A. Gibbs, D. M. Muzny, S. E. Scherer, J. B. Bouck, E. J. Sodergren, K. C. Worley, C. M. Rives, J. H. Gorrell, M. L. Metzker, S. L. Naylor, R. S. Kucherlapati, D. L. Nelson, G. M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, T. Yada, A. Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J. Weissenbach, R. Heilig, W. Saurin, F. Artiguenave, P. Brottier, T. Bruls, E. Pelletier, C. Robert, P. Wincker, D. R. Smith, L. Doucette-Stamm, M. Rubenfield, K. Weinstock, H. M. Lee, J. Dubois, A. Rosenthal, M. Platzer, G. Nyakatura, S. Taudien, A. Rump, H. Yang, J. Yu, J. Wang, G. Huang, J. Gu, L. Hood, L. Rowen, A. Madan, S. Qin, R. W. Davis, N. A. Federspiel, A. P. Abola, M. J. Proctor, R. M. Myers, J. Schmutz, M. Dickson, J. Grimwood, D. R. Cox, M. V. Olson, R. Kaul, N. Shimizu, K. Kawasaki, S. Minoshima, G. A. Evans, M. Athanasiou, R. Schultz, B. A. Roe, F. Chen, H. Pan, J. Ramser, H. Lehrach, R. Reinhardt, W. R. McCombie, M. de la Bastide, N. Dedhia, H. Blocker, K. Hornischer, G. Nordsiek, R. Agarwala, L. Aravind, J. A. Bailey, A. Bateman, S. Batzoglou, E. Birney, P. Bork, D. G. Brown, C. B. Burge, L. Cerutti, H. C. Chen, D. Church, M. Clamp, R. R. Copley, T. Doerks, S. R. Eddy, E. E. Eichler, T. S. Furey, J. Galagan, J. G. Gilbert, C. Harmon, Y. Hayashizaki, D. Haussler, H. Hermjakob, K. Hokamp, W. Jang, L. S. Johnson, T. A. Jones, S. Kasif, A. Kaspryzk, S. Kennedy, W. J. Kent, P. Kitts, E. V. Koonin, I. Korf, D. Kulp, D. Lancet, T. M. Lowe, A. McLysaght, T. Mikkelsen, J. V. Moran, N. Mulder, V. J. Pollara, C. P. Ponting, G. Schuler, J. Schultz, G. Slater, A. F. Smit, E. Stupka, J. Szustakowski, D. Thierry-Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, R. Wheeler, A. Williams, Y. I. Wolf, K. H. Wolfe, S. P. Yang, R. F. Yeh, F. Collins, M. S. Guyer, J. Peterson, A. Felsenfeld, K. A. Wetterstrand, A. Patrinos, M. J. Morgan, P. de Jong, J. J. Catanese, K. Osoegawa, H. Shizuya, S. Choi, and Y. J. Chen, Initial sequencing and analysis of the human genome. Nature 409, 860 (2001).
3. T. Tokatlian and T. Segura, siRNA applications in nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 305 (2010).
4. A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806 (1998).
5. G. J. Hannon and J. J. Rossi, Unlocking the potential of the human genome with RNA interference. Nature 431, 371 (2004).
6. V. N. Kim, MicroRNA biogenesis: Coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376 (2005).
7. A. Krek, D. Grun, M. N. Poy, R. Wolf, L. Rosenberg, E. J. Epstein, P. MacMenamin, I. da Piedade, K. C. Gunsalus, M. Stoffel, and N. Rajewsky, Combinatorial microRNA target predictions. Nat. Genet. 37, 495 (2005).
8. M. Amarzguioui, J. J. Rossi, and D. Kim, Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett. 579, 5974 (2005).
9. A. de Fougerolles, H. P. Vornlocher, J. Maraganore, and J. Lieberman, Interfering with disease: A progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443 (2007).
10. B. L. Davidson and P. B. McCray, Jr., Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329 (2011).
11. J. H. Jeong, H. Mok, Y. K. Oh, and T. G. Park, siRNA conjugate delivery systems. Bioconjug. Chem. 20, 5 (2009).
12. A. Sato, S. W. Choi, M. Hirai, A. Yamayoshi, R. Moriyama, T. Yamano, M. Takagi, A. Kano, A. Shimamoto, and A. Maruyama, Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life. J. Control. Release 122, 209 (2007).
13. K. Buyens, S. C. De Smedt, K. Braeckmans, J. Demeester, L. Peeters, L. A. van Grunsven, X. de Mollerat du Jeu, R. Sawant, V. Torchilin, K. Farkasova, M. Ogris, and N. N. Sanders, Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. J. Control. Release 158, 362 (2012).
14. F. Iversen, C. Yang, F. Dagnaes-Hansen, D. H. Schaffert, J. Kjems, and S. Gao, Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 3, 201 (2013).
15. M. Elsabahy, R. Shrestha, C. Clark, S. Taylor, J. Leonard, and K. L. Wooley, Multifunctional hierarchically assembled nanostructures as complex stage-wise dual-delivery systems for coincidental yet differential trafficking of siRNA and paclitaxel. Nano Lett. 13, 2172 (2013).
16. D. W. Dong, B. Xiang, W. Gao, Z. Z. Yang, J. Q. Li, and X. R. Qi, pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Biomaterials 34, 4849 (2013).
17. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505 (2008).
18. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R. K. Pandey, T. Racie, K. G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, and H. P. Vornlocher, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173 (2004).
19. L. Li and Y. Shen, Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin. Biol. Ther. 9, 609 (2009).
20. J. M. Harris and R. B. Chess, Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214 (2003).
21. S. C. Semple, T. O. Harasym, K. A. Clow, S. M. Ansell, S. K. Klimuk, and M. J. Hope, Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J. Pharmacol. Exp. Ther. 312, 1020 (2005).
22. Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387 (1986).
23. D. B. Kirpotin, D. C. Drummond, Y. Shao, M. R. Shalaby, K. Hong, U. B. Nielsen, J. D. Marks, C. C. Benz, and J. W. Park, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732 (2006).
24. J. S. Remy, C. Sirlin, P. Vierling, and J. P. Behr, Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjug. Chem. 5, 647 (1994).
25. O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, and J. P. Behr, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 92, 7297 (1995).
26. M. Dominska and D. M. Dykxhoorn, Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci. 123, 1183 (2010).
27. R. A. Parente, S. Nir, and F. C. Szoka, Jr., Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA. Biochemistry 29, 8720 (1990).
28. H. W. Huang, F. Y. Chen, and M. T. Lee, Molecular mechanism of Peptide-induced pores in membranes. Phys. Rev. Lett. 92, 198304 (2004).
29. M. Thibault, S. Nimesh, M. Lavertu, and M. D. Buschmann, Intracellular trafficking and decondensation kinetics of chitosan-pDNA polyplexes. Mol. Ther. 18, 1787 (2010).
30. S. P. Strand, S. Lelu, N. K. Reitan, C. de Lange Davies, P. Artursson, and K. M. Varum, Molecular design of chitosan gene delivery systems with an optimized balance between polyplex stability and polyplex unpacking. Biomaterials 31, 975 (2010).
31. C. L. Waite, S. M. Sparks, K. E. Uhrich, and C. M. Roth, Acetylation of PAMAM dendrimers for cellular delivery of siRNA. BMC Biotechnol. 9, 38 (2009).
32. T. E. Tjelle, A. Brech, L. K. Juvet, G. Griffiths, and T. Berg, Isolation and characterization of early endosomes, late endosomes and terminal lysosomes: Their role in protein degradation. J. Cell Sci. 109, 2905 (1996).
33. K. A. Howard, Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug. Deliv. Rev. 61, 710 (2009).
34. A. Daka and D. Peer, RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug. Deliv. Rev. 64, 1508 (2012).
35. N. Saranya, A. Moorthi, S. Saravanan, M. P. Devi, and N. Selvamurugan, Chitosan and its derivatives for gene delivery. Int. J. Biol. Macromol. 48, 234 (2011).
36. M. Koping-Hoggard, K. M. Varum, M. Issa, S. Danielsen, B. E. Christensen, B. T. Stokke, and P. Artursson, Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene. Ther. 11, 1441 (2004).
37. M. Lavertu, S. Methot, N. Tran-Khanh, and M. D. Buschmann, High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 27, 4815 (2006).
38. K. Bowman and K. W. Leong, Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomedicine 1, 117 (2006).
39. W. E. Rudzinski and T. M. Aminabhavi, Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 399, 1 (2010).
40. H. de Martimprey, J. R. Bertrand, C. Malvy, P. Couvreur, and C. Vauthier, New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm. Res. 27, 498 (2010).
41. M. S. Huh, S. Y. Lee, S. Park, S. Lee, H. Chung, Y. Choi, Y. K. Oh, J. H. Park, S. Y. Jeong, K. Choi, K. Kim, and I. C. Kwon, Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J. Control. Release 144, 134 (2010).
42. H. D. Han, E. M. Mora, J. W. Roh, M. Nishimura, S. J. Lee, R. L. Stone, M. Bar-Eli, G. Lopez-Berestein, and A. K. Sood, Chitosan hydrogel for localized gene silencing. Cancer Biol. Ther. 11, 839 (2011).
43. E. Salva, L. Kabasakal, F. Eren, N. Ozkan, F. Cakalagaoglu, and J. Akbuga, Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo. Nucleic Acid Ther. 22, 40 (2012).
44. S. Mao, W. Sun, and T. Kissel, Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug. Deliv. Rev. 62, 12 (2010).
45. H. Katas and H. O. Alpar, Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 115, 216 (2006).
46. H. S. Yoo, J. E. Lee, H. Chung, I. C. Kwon, and S. Y. Jeong, Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery. J. Control. Release 103, 235 (2005).
47. D. Lee, W. Zhang, S. A. Shirley, X. Kong, G. R. Hellermann, R. F. Lockey, and S. S. Mohapatra, Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery. Pharm. Res. 24, 157 (2007).
48. F. Q. Hu, M. D. Zhao, H. Yuan, J. You, Y. Z. Du, and S. Zeng, A novel chitosan oligosaccharide-stearic acid micelles for gene delivery: Properties and in vitro transfection studies. Int. J. Pharm. 315, 158 (2006).
49. Y. Zhang, J. Chen, Y. Pan, J. Zhao, L. Ren, M. Liao, Z. Hu, L. Kong, and J. Wang, A novel PEGylation of chitosan nanoparticles for gene delivery. Biotechnol. Appl. Biochem. 46, 197 (2007).
50. K. Wong, G. Sun, X. Zhang, H. Dai, Y. Liu, C. He, and K. W. Leong, PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. Bioconjug. Chem. 17, 152 (2006).
51. J. Y. Pille, H. Li, E. Blot, J. R. Bertrand, L. L. Pritchard, P. Opolon, A. Maksimenko, H. Lu, J. P. Vannier, J. Soria, C. Malvy, and C. Soria, Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: Safety and efficacy in xenografted aggressive breast cancer. Hum. Gene. Ther. 17, 1019 (2006).
52. H. V. Jagani, V. R. Josyula, V. R. Palanimuthu, R. C. Hariharapura, and S. S. Gang, Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating. Eur. J. Pharm. Sci. 48, 611 (2013).
53. M. E. Davis and M. E. Brewster, Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discov. 3, 1023 (2004).
54. H. Gonzalez, S. J. Hwang, and M. E. Davis, New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 10, 1068 (1999).
55. C. Ortiz Mellet, J. M. Garcia Fernandez, and J. M. Benito, Cyclodextrin-based gene delivery systems. Chem. Soc. Rev. 40, 1586 (2011).
56. S. H. Pun, N. C. Bellocq, A. Liu, G. Jensen, T. Machemer, E. Quijano, T. Schluep, S. Wen, H. Engler, J. Heidel, and M. E. Davis, Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug. Chem. 15, 831 (2004).
57. F. Kihara, H. Arima, T. Tsutsumi, F. Hirayama, and K. Uekama, In vitro and in vivo gene transfer by an optimized alpha-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug. Chem. 14, 342 (2003).
58. H. Arima, A. Yoshimatsu, H. Ikeda, A. Ohyama, K. Motoyama, T. Higashi, A. Tsuchiya, T. Niidome, Y. Katayama, K. Hattori, and T. Takeuchi, Folate-PEG-appended dendrimer conjugate with alpha-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol. Pharm. 9, 2591 (2012).
59. A. D. Baldwin and K. L. Kiick, Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers 94, 128 (2010).
60. R. Mehvar, Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 69, 1 (2000).
61. L. Cui, J. L. Cohen, C. K. Chu, P. R. Wich, P. H. Kierstead, and J. M. Frechet, Conjugation chemistry through acetals toward a dextran-based delivery system for controlled release of siRNA. J. Am. Chem. Soc. 134, 15840 (2012).
62. G. Y. Wu and C. H. Wu, Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochemistry 27, 887 (1988).
63. N. Emi, S. Kidoaki, K. Yoshikawa, and H. Saito, Gene transfer mediated by polyarginine requires a formation of big carriercomplex of DNA aggregate. Biochem. Biophys. Res. Commun. 231, 421 (1997).
64. T. K. T. Hashimoto, T. Nagasaki, A. Murakami, and T. Yamaoka, Quantitative comparison between poly(L-arginine) and poly(Llysine) at each step of polyplex-based gene transfection using a microinjection technique. Sci. Technol. Adv. Mater. 13, 9 (2012).
65. C. Tros de Ilarduya, Y. Sun, and N. Duzgunes, Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 40, 159 (2010).
66. Z. X. Zhao, S. Y. Gao, J. C. Wang, C. J. Chen, E. Y. Zhao, W. J. Hou, Q. Feng, L. Y. Gao, X. Y. Liu, L. R. Zhang, and Q. Zhang, Self-assembly nanomicelles based on cationic mPEGPLA- b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials 33, 6793 (2012).
67. P. Liu, H. Yu, Y. Sun, M. Zhu, and Y. Duan, A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 33, 4403 (2012).
68. J. Luten, C. F. van Nostrum, S. C. De Smedt, and W. E. Hennink, Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release 126, 97 (2008).
69. R. Kircheis, L. Wightman, and E. Wagner, Design and gene delivery activity of modified polyethylenimines. Adv. Drug. Deliv. Rev. 53, 341 (2001).
70. M. Gunther, J. Lipka, A. Malek, D. Gutsch, W. Kreyling, and A. Aigner, Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur. J. Pharm. Biopharm. 77, 438 (2011).
71. M. A. Gosselin, W. Guo, and R. J. Lee, Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug. Chem. 12, 989 (2001).
72. S. Mao, M. Neu, O. Germershaus, O. Merkel, J. Sitterberg, U. Bakowsky, and T. Kissel, Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft- poly(ethylene glycol) block copolymer/ SiRNA polyplexes. Bioconjug. Chem. 17, 1209 (2006).
73. A. Beyerle, A. Braun, O. Merkel, F. Koch, T. Kissel, and T. Stoeger, Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J. Control. Release 151, 51 (2011).
74. L. Zhang, C. H. Hu, S. X. Cheng, and R. X. Zhuo, PEI grafted hyperbranched polymers with polyglycerol as a core for gene delivery. Colloids Surf. B Biointerfaces 76, 427 (2010).
75. Y. B. Patil, S. K. Swaminathan, T. Sadhukha, L. Ma, and J. Panyam, The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31, 358 (2010).
76. D. Appelhans, H. Komber, M. A. Quadir, S. Richter, S. Schwarz, J. van der Vlist, A. Aigner, M. Muller, K. Loos, J. Seidel, K. F. Arndt, R. Haag, and B. Voit, Hyperbranched PEI with various oligosaccharide architectures: Synthesis, characterization, ATP complexation, and cellular uptake properties. Biomacromolecules 10, 1114 (2009).
77. S. Hobel, A. Loos, D. Appelhans, S. Schwarz, J. Seidel, B. Voit, and A. Aigner, Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes. J. Control. Release 149, 146 (2011).
78. A. Zintchenko, A. Philipp, A. Dehshahri, and E. Wagner, Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug. Chem. 19, 1448 (2008).
79. C. H. Lee, Y. H. Ni, C. C. Chen, C. Chou, and F. H. Chang, Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells. Biochim. Biophys. Acta. 1611, 55 (2003).
80. J. Schafer, S. Hobel, U. Bakowsky, and A. Aigner, Liposome- polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials 31, 6892 (2010).
81. J. Pelisek, L. Gaedtke, J. DeRouchey, G. F. Walker, S. Nikol, and E. Wagner, Optimized lipopolyplex formulations for gene transfer to human colon carcinoma cells under in vitro conditions. J. Gene. Med. 8, 186 (2006).
82. O. Taratula, O. B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, and T. Minko, Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control Release 140, 284 (2009).
83. T. I. Kim, H. J. Seo, J. S. Choi, H. S. Jang, J. U. Baek, K. Kim, and J. S. Park, PAMAM-PEG-PAMAM: novel triblock copolymer as a biocompatible and efficient gene delivery carrier. Biomacromolecules 5, 2487 (2004).
84. K. Watanabe, M. Harada-Shiba, A. Suzuki, R. Gokuden, R. Kurihara, Y. Sugao, T. Mori, Y. Katayama, and T. Niidome, In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. Mol. Biosyst. 5, 1306 (2009).
85. H. Baigude, J. McCarroll, C. S. Yang, P. M. Swain, and T. M. Rana, Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. 2, 237 (2007).
86. W. Fischer, M. Calderon, A. Schulz, I. Andreou, M. Weber, and R. Haag, Dendritic polyglycerols with oligoamine shells show low toxicity and high siRNA transfection efficiency in vitro. Bioconjug. Chem. 21, 1744 (2010).
87. P. Ofek, W. Fischer, M. Calderon, R. Haag, and R. Satchi-Fainaro, In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J. 24, 3122 (2010).
88. K. Jain, P. Kesharwani, U. Gupta, and N. K. Jain, Dendrimer toxicity: Let's meet the challenge. Int. J. Pharm. 394, 122 (2010).
89. R. Jevprasesphant, J. Penny, R. Jalal, D. Attwood, N. B. McKeown, and A. D'Emanuele, The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252, 263 (2003).
90. R. B. Kolhatkar, K. M. Kitchens, P. W. Swaan, and H. Ghandehari, Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug. Chem. 18, 2054 (2007).
91. Z. Amoozgar and Y. Yeo, Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4, 219 (2012).
92. S. H. Kim, J. H. Jeong, S. H. Lee, S. W. Kim, and T. G. Park, PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116, 123 (2006).
93. K. L. Heredia, T. H. Nguyen, C. W. Chang, V. Bulmus, T. P. Davis, and H. D. Maynard, Reversible siRNA-polymer conjugates by RAFT polymerization. Chem. Commun. (Camb) 3245 (2008).
94. K. Gunasekaran, T. H. Nguyen, H. D. Maynard, T. P. Davis, and V. Bulmus, Conjugation of siRNA with comb-type PEG enhances serum stability and gene silencing efficiency. Macromol. Rapid. Commun. 32, 654 (2011).
95. M. Oishi, Y. Nagasaki, K. Itaka, N. Nishiyama, and K. Kataoka, Lactosylated poly(ethylene glycol)-siRNA conjugate through acidlabile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127, 1624 (2005).
96. S. H. Lee, H. Mok, and T. G. Park, Di- and triblock siRNA-PEG copolymers: PEG density effect of polyelectrolyte complexes on cellular uptake and gene silencing efficiency. Macromol. Biosci. 11, 410 (2011).
97. H. K. Makadia and S. J. Siegel, Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) 3, 1377 (2011).
98. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Preat, PLGA-based nanoparticles: An overview of biomedical applications. J. Control Release 161, 505 (2012).
99. J. Kopecek, P. Kopeckova, T. Minko, and Z. Lu, HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61 (2000).
100. R. Duncan, P. Kopeckova-Rejmanova, J. Strohalm, I. Hume, H. C. Cable, J. Pohl, J. B. Lloyd, and J. Kopecek, Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer 55, 165 (1987).
101. L. W. Seymour, P. A. Flanagan, A. Al-Shamkhani, V. Subr, K. Ulbrich, J. Cassidy, and R. Duncan, Synthetic polymers conjugated to monoclonal antibodies: Vehicles for tumour-targeted drug delivery. Sel. Cancer Ther. 7, 59 (1991).
102. M. Kovar, T. Mrkvan, J. Strohalm, T. Etrych, K. Ulbrich, M. Stastny, and B. Rihova, HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. J. Control. Release 92, 315 (2003).
103. K. Miller, R. Erez, E. Segal, D. Shabat, and R. Satchi-Fainaro, Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. Engl. 48, 2949 (2009).
104. D. Oupicky, C. Konak, K. Ulbrich, M. A. Wolfert, and L. W. Seymour, DNA delivery systems based on complexes of DNA with synthetic polycations and their copolymers. J. Control. Release 65, 149 (2000).
105. J. Shi, R. N. Johnson, J. G. Schellinger, P. M. Carlson, and S. H. Pun, Reducible HPMA-co-oligolysine copolymers for nucleic acid delivery. Int. J. Pharm. 427, 113 (2012).
106. R. N. Johnson, D. S. Chu, J. Shi, J. G. Schellinger, P. M. Carlson, and S. H. Pun, HPMA-oligolysine copolymers for gene delivery: optimization of peptide length and polymer molecular weight. J. Control. Release 155, 303 (2011).
107. Z. Qin, W. Liu, L. Guo, and X. Li, Preparation and characterization of guanidinated N-3-aminopropyl methacrylamide-N-2-hydroxypropyl methacrylamide copolymers as gene delivery carriers. J. Control. Release 152 Suppl 1, e168 (2011).
108. S. Kirkland-York, Y. Zhang, A. E. Smith, A. W. York, F. Huang, and C. L. McCormick, Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition-fragmentation chain transfer polymers. Biomacromolecules 11, 1052 (2010).
109. L. Wang, J. Kristensen, and D. E. Ruffner, Delivery of antisense oligonucleotides using HPMA polymer: Synthesis of A thiol polymer and its conjugation to water-soluble molecules. Bioconjug. Chem. 9, 749 (1998).
110. A. W. York, F. Huang, and C. L. McCormick, Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers. Biomacromolecules 11, 505 (2010).
111. E. P. Feener, W. C. Shen, and H. J. Ryser, Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes. J. Biol. Chem. 265, 18780 (1990).
112. K. D. Jensen, P. Kopeckova, and J. Kopecek, Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. Bioconjug. Chem. 13, 975 (2002).
113. J. Guo, J. R. Ogier, S. Desgranges, R. Darcy, and C. O'Driscoll, Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 33, 7775 (2012).
114. L. K. A. Ribas, J. D. Heidel, J. Peterkin, D. B. Seligson, J. E. Zuckerman, C. Choi, Y. Yen, M. E. Davis, and A. W. Tolcher, Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial., in 2010 ASCO Annual Meeting. J. Clin. Oncol. 28, 15s (2010).
115. M. E. Davis, J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, and A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067 (2010).
116. R. Namgung and W. J. Kim, A highly entangled polymeric nanoconstruct assembled by siRNA and its reduction-triggered siRNA release for gene silencing. Small 8, 3209 (2012).
117. R. J. Christie, Y. Matsumoto, K. Miyata, T. Nomoto, S. Fukushima, K. Osada, J. Halnaut, F. Pittella, H. J. Kim, N. Nishiyama, and K. Kataoka, Targeted Polymeric Micelles for siRNA Treatment of Experimental Cancer by Intravenous Injection. ACS Nano 6, 5174 (2012).
118. L. Wang, J. Shi, H. Zhang, H. Li, Y. Gao, Z. Wang, H. Wang, L. Li, C. Zhang, C. Chen, Z. Zhang, and Y. Zhang, Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes. Biomaterials 34, 262 (2013).
119. W. Xia, P. Wang, C. Lin, Z. Li, X. Gao, G. Wang, and X. Zhao, Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo. J. Control. Release 157, 427 (2012).
120. M. Han, Q. Lv, X. J. Tang, Y. L. Hu, D. H. Xu, F. Z. Li, W. Q. Liang, and J. Q. Gao, Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J. Control. Release 163, 136 (2012).
121. S. Biswas, P. P. Deshpande, G. Navarro, N. S. Dodwadkar, and V. P. Torchilin, Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials 34, 1289 (2013).
122. J. Zhou, T. R. Patel, M. Fu, J. P. Bertram, and W. M. Saltzman, Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33, 583 (2012).
123. C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart, and M. Press, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719 (2002).
124. B. J. Druker, F. Guilhot, S. G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. W. Deininger, R. T. Silver, J. M. Goldman, R. M. Stone, F. Cervantes, A. Hochhaus, B. L. Powell, J. L. Gabrilove, P. Rousselot, J. Reiffers, J. J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. L. Nielsen, J. P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, and R. A. Larson, Five-year followup of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408 (2006).
125. H. Asahina, K. Yamazaki, I. Kinoshita, N. Sukoh, M. Harada, H. Yokouchi, T. Ishida, S. Ogura, T. Kojima, Y. Okamoto, Y. Fujita, H. Dosaka-Akita, H. Isobe, and M. Nishimura, A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95, 998 (2006).
126. R. C. Heel, R. N. Brogden, T. M. Speight, and G. S. Avery, Tamoxifen: A review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16, 1 (1978).
127. B. Vogelstein and K. W. Kinzler, Cancer genes and the pathways they control. Nat. Med. 10, 789 (2004).
128. S. I. Pai, Y. Y. Lin, B. Macaes, A. Meneshian, C. F. Hung, and T. C. Wu, Prospects of RNA interference therapy for cancer. Gene. Ther. 13, 464 (2006).
129. N. Ferrara, Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl 1, 2 (2004).
130. O. Taratula, O. B. Garbuzenko, A. M. Chen, and T. Minko, Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug. Target. 19, 900 (2011).
131. J. B. Fleming, G. L. Shen, S. E. Holloway, M. Davis, and R. A. Brekken, Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy. Mol. Cancer Res. 3, 413 (2005).
132. A. Fernandez-Medarde and E. Santos, Ras in cancer and developmental diseases. Genes. Cancer 2, 344 (2011).
133. J. Folkman, Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182 (1971).
134. E. Segal, H. Pan, P. Ofek, T. Udagawa, P. Kopeckova, J. Kopecek, and R. Satchi-Fainaro, Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 4, e5233 (2009).
135. B. Yu, H. C. Tai, W. Xue, L. J. Lee, and R. J. Lee, Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 27, 286 (2010).
136. T. R. Daniels, E. Bernabeu, J. A. Rodriguez, S. Patel, M. Kozman, D. A. Chiappetta, E. Holler, J. Y. Ljubimova, G. Helguera, and M. L. Penichet, The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta. 1820, 291 (2012).
137. G. Russell-Jones, K. McTavish, J. McEwan, J. Rice, and D. Nowotnik, Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J. Inorg. Biochem. 98, 1625 (2004).
138. F. Danhier, A. Le Breton, and V. Preat, RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9, 2961 (2012).